Scientific Review Board

The Scientific Review Board reviews all grant applications submitted to the ADDF. It is composed of over 150 scientists who possess expertise in multiple areas of Alzheimer’s research.

  • Carmela Abraham, PhD
    Boston University School of Medicine

  • Larry D. Altstiel, MD, PhD
    Provectra Therapeutics, Inc.

  • Ottavio Arancio, MD, PhD
    Columbia University

  • Kelly Bales, PhD
    Pfizer Inc

  • Nir Barzilai, MD
    Albert Einstein College of Medicine

  • Guriq Basi, PhD
    Elan Pharmaceuticals

  • Dirk Beher, PhD
    Asceneuron SA

  • David A. Bennett, MD
    Rush University Medical Center

  • Narayan Bhat, PhD
    Medical University of South Carolina

  • Jennifer Bizon, PhD
    McKnight Brain Research Foundation

  • Chas Bountra, PhD
    University of Oxford

  • Adam Boxer, MD, PhD
    University of California, San Francisco

  • Roberta Diaz Brinton, PhD
    Chair in Therapeutic Discovery and Development and Professor of Pharmacology and Pharmaceutical Sciences, Biomedical Engineering and Neurology, University of Southern California

  • Tilmann Brotz, PhD
    Konzept Drug Development Consulting

  • Kurt Brunden, PhD
    University of Pennsylvania

  • Nigel Cairns, PhD
    Washington University

  • Thomas Chung, PhD
    Sanford-Burnham Medical Research Institute

  • John Cirrito, PhD
    Washington University, St. Louis

  • Thomas Cirrito, PhD
    Stemline Therapeutics, Inc.

  • Mark A. Cochran, PhD
    Johns Hopkins University School of Medicine